Oscotec Inc. (KOSDAQ:039200)

Market Cap	2.00T +68.8%
Revenue (ttm)	99.84B +193.6%
Net Income	52.34B +5,871.6%
EPS	1,368.00 +5,868.9%
Shares Out	38.26M
PE Ratio	38.30
Forward PE	82.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	209,623
Average Volume	312,979
Open	52,400
Previous Close	52,400
Day's Range	51,300 - 54,200
52-Week Range	25,000 - 66,000
Beta	1.31
RSI	52.87
Earnings Date	May 12, 2026

About Oscotec

Oscotec Inc. operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses. It develops SKI-O-703, a SYK inhibitor that is in Phase 2 clinical trials to treat rheumatoid arthritis and idiopathic thrombocytopenic purpura; SKI-G-801, a selective FLT3/AXL inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia, as well as other solid tumors; and lazertinib, a 3rd generation EGFR inhibitor that is in Phase 3 clinical trials...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Employees: 53
• Stock Exchange: KOSDAQ
• Ticker Symbol: 039200

Financial Performance

In 2025, Oscotec's revenue was 99.84 billion, an increase of 193.58% compared to the previous year's 34.01 billion. Earnings were 52.34 billion, an increase of 5871.65%.